Botulinum Neurotoxin Type A for the Treatment of Benign Prostatic Hyperplasia: Randomized Study Comparing Two Doses
Table 2
Mean and percentage change from baseline of International Prostatic Symptom Score (IPSS), maximum urinary flow rate (), pos-void residual volume (PVR), PSA levels and prostate volume after 3 and 6 months of treatment.
BoNT-A 100 U
Change %
BoNT-A 200 U
Change %
P value†
IPSS
Baseline
22.1 ± 6.4
22.8 ± 6.9
3rd month
8.0 ± 4.4*
−64%
9.5 ± 4.2*
−58%
0.767
6th month
7.5 ± 4.3*
−66%
9.2 ± 3.4*
−60%
0.657
(mL/s)
Baseline
8.6 ± 3.1
8.4 ± 3.2
3rd month
12.8 ± 3.6*
49%
11.2 ± 4.8*
33%
0.564
6th month
10.9 ± 3.4*
27%
11.4 ± 3.2*
36%
0.927
PVR (mL)
Baseline
131.8 ± 65.0
121.1 ± 73.7
3rd mo
39.1 ± 33.5*
−70%
48.1 ± 24.4*
−60%
0.466
6th mo
38.5 ± 31.2*
−69%
51.7 ± 24.7*
−57%
0.311
PSA (ng/dL)
Baseline
3.9 ± 4.1
4.1 ± 2.7
3rd mo
3.2 ± 3.3 ns
−18%
3.0 ± 2.1*
−27%
0.426
6th mo
3.0 ± 2.5*
−23%
2.7 ± 1.7*
−34%
0.421
Prostate volume (mL)
Baseline
42.3 ± 18.5
43.1 ± 19.7
3rd mo
38.9 ± 16.1 ns
−8%
39.8 ± 17.7 ns
−8%
0.961
6th mo
38.6 ± 16.6 ns
−9%
37.8 ± 15.5*
−13%
0.561
†Statistical significance between groups (intergroup comparison) (Student's t-test). Statistical significance within groups: *P < 0.05 versus baseline, ns (not significance versus baseline). (Repeated measures ANOVA and Dunnett's posttest).
